Government ministries are in talks over drug data protection rules. This issue involves domestic drug makers, global pharma giants, and patient advocates. Discussions are ongoing to find a balance. The outcome could impact access to affordable medicines for Indian patients. Investment deals are also linked to this decision. A final decision is pending.
